evenfolio

Healthcare · NSE: NATCOPHARM

Natco Pharma

Q2 FY27 earnings highlights, from the results presentation

Price as of 16 Nov 2026
828.65+2.25%
M.Cap
₹14,842Cr
P/E
17.9×
1Y return
+1.97%
From 52W high
−32.5%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue9671,363-29.0%735+31.6%
EBITDA258579-55.5%187+38.3%
EBITDA margin26.7%42.5%-1583 bps25.4%+129 bps
PBTProfit before tax243614-60.4%186+31.0%
Net profit203518-60.9%207-1.9%
EPS (₹)11.3128.94-60.9%11.53-1.9%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

In short

  1. 01International formulations revenue was INR 6,684 Mn against INR 11,402 Mn a year earlier.
  2. 02Profit after share of associate was INR 2,026 Mn; EPS was INR 11.31.
  3. 03NATCO bought an additional 13.25% of Adcock Ingram, taking its holding to 49%; profit share was INR 292 Mn.
  4. 04NATCO invested a further US$ 16.7 million in eGenesis, taking the total to US$ 24.7 million.
  5. 05FDA cleared eGenesis's kidney xenotransplant Phase 1/2/3 study; a 33-patient registration study is to be initiated.

Segments

International Formulations: International formulations revenue was INR 6,684 Mn in the quarter

Slides · p. 4
“International Formulations at INR 6,684 Mn”

Formulation – Domestic: Domestic formulation revenue INR 1,457 Mn vs 1,054 Mn a year earlier and 1,364 Mn prior quarter

Slides · p. 6
“Formulation – Domestic 1,457 1,054 1,364”

API: API revenue INR 613 Mn vs 539 Mn a year earlier and 667 Mn prior quarter

Slides · p. 6
“API Revenue 613 539 667”

Crop Health Sciences: Crop Health Sciences revenue INR 610 Mn vs 524 Mn a year earlier and 408 Mn prior quarter

Slides · p. 6
“Crop Health Sciences 610 524 408”

Pharmaceutical Formulations: Pharmaceutical formulations total revenue INR 8,141 Mn vs 12,456 Mn and 6,135 Mn

Slides · p. 6
“Pharmaceutical Formulations Total Revenue 8,141 12,456 6,135”

Margins and costs

EBITDA was INR 3,100 Mn and EBITDA margin 30.4% in the quarter

Slides · p. 4
“Earnings Before Interest Tax Depreciation and Amortization (EBITDA)* stood at INR 3,100 Mn and EBITDA Margin at 30.4%”

EBITDA margin 30.4% vs 46.4% a year earlier and 30.9% prior quarter

Slides · p. 7
“EBITDA margin* (%) 30.4% 46.4% 30.9%”

EBITDA INR 3,100 Mn vs 6,792 Mn and 2,457 Mn

Slides · p. 7
“Earnings before interest, tax, depreciation and amortization (EBITDA) 3,100 6,792 2,457”

Total expenses before finance cost and depreciation INR 7,094 Mn vs 7,838 Mn and 5,487 Mn

Slides · p. 7
“Total Expenses (before finance cost and depreciation) 7,094 7,838 5,487”

Debt and working capital

Finance cost INR 176 Mn vs 131 Mn a year earlier and 130 Mn prior quarter

Slides · p. 7
“Finance cost 176 131 130”

Acquisitions and new business

NATCO acquired an additional 13.25% stake in Adcock Ingram during the quarter

Slides · p. 4
“During the quarter, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to”

Adcock Ingram Holdings: Holding in Adcock Ingram at 49%; profit share from it INR 292 Mn in Q2FY27

Slides · p. 4
“49%. Profit Share From Our Associate Adcock Ingram Holdings Ltd for Q2FY27 Stood at INR 292 Mn”

Invested additional US$ 16.7 million in eGenesis; total investment US$ 24.7 million

Slides · p. 4
“Invested Additional US$ 16.7 million in eGenesis, Inc., NATCO’s Total Investment in eGenesis amounts to US$ 24.7 million”

Share of associate profit INR 292 Mn in the quarter vs 843 Mn prior quarter

Slides · p. 7
“Share of profit of associate (net of tax) 292 - 843”

eGenesis: FDA cleared eGenesis Phase 1/2/3 clinical study for kidney xenotransplantation

Slides · p. 9
“FDA has cleared the Phase 1/2/3 clinical study for kidney”

Other

Total revenue for Q2FY27 was INR 10,194 Mn

Slides · p. 4
“Total Revenue for Q2FY27 stood at INR 10,194 Mn”

Profit after share of profit of associate was INR 2,026 Mn in Q2FY27

Slides · p. 4
“Profit After Share of Profit of Associate for Q2FY27 stood at INR 2,026 Mn”

EPS for Q2FY27 was INR 11.31 per share

Slides · p. 4
“Earnings Per Share (EPS) for Q2FY27 stood at INR 11.31 per share”

Consolidated total revenue INR 10,194 Mn vs 14,630 Mn a year earlier and 7,944 Mn prior quarter

Slides · p. 6
“Consolidated Total Revenue 10,194 14,630 7,944”

Other operating and non-operating income INR 831 Mn vs 1,111 Mn a year earlier

Slides · p. 6
“Other operating & non-operating income 831 1,111 734”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools